- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/00 - Antineoplastic agents
Patent holdings for IPC class A61P 35/00
Total number of patents in this class: 94003
10-year publication summary
|
2900
|
3430
|
3516
|
5612
|
7778
|
8470
|
9279
|
10241
|
10118
|
3153
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11238 |
1018 |
| F. Hoffmann-La Roche AG | 7958 |
749 |
| The Regents of the University of California | 18943 |
739 |
| Genentech, Inc. | 3742 |
714 |
| Bristol-myers Squibb Company | 5080 |
659 |
| Dana-Farber Cancer Institute, Inc. | 2455 |
589 |
| Merck Patent GmbH | 5909 |
551 |
| AstraZeneca AB | 3042 |
525 |
| Board of Regents, The University of Texas System | 5370 |
495 |
| Janssen Pharmaceutica N.V. | 3839 |
439 |
| Memorial Sloan-Kettering Cancer Center | 1789 |
433 |
| The Johns Hopkins University | 5377 |
417 |
| Amgen Inc. | 3779 |
413 |
| Bayer Pharma AG | 1096 |
409 |
| Takeda Pharmaceutical Company Limited | 2961 |
406 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
405 |
| Pfizer Inc. | 3322 |
399 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
387 |
| Centre National de La Recherche Scientifique | 9632 |
386 |
| Incyte Corporation | 918 |
382 |
| Other owners | 83488 |